Novartis: migraine drug accepted for review in Europe.

(CercleFinance.com) - Novartis today said that the European Medicines Agency (EMA) has accepted to review the company's marketing authorisation application for AMG 334 (erenumab), a drug for the prevention of migraine.


The Swiss firm said that the submission includes data from four Phase II and III clinical studies involving over 2,600 patients experiencing four or more migraine days per month.

Novartis and Amgen plan to jointly market AMG 334 (erenumab) in the US, with Novartis keeping exclusive marketing rights in the rest of the world.

The biopharmaceutical company stresses a "significant unmet need" for people with migraine, who have had "very few new treatment options since the 1990s."


Copyright (c) 2017 CercleFinance.com. All rights reserved.